| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Human melatonin receptor 1 and melatonin receptor 2. Ramelteon metabolite M-II is a potent agonist at these receptors.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Ramelteon metabolite M-II, the non-deuterated form, exhibits IC50 values of 208 pM for human melatonin receptor 1 and 1470 pM for human melatonin receptor 2. The deuterated form, Ramelteon metabolite M-II-d3, is expected to exhibit similar pharmacological properties due to the minimal isotopic effect of deuterium substitution. |
| ln Vivo |
Ramelteon metabolite M-II is the major active metabolite of ramelteon and contributes to the pharmacological activity of the parent drug in vivo. Ramelteon is used for the treatment of insomnia characterized by difficulty with sleep onset.
|
| Enzyme Assay |
In vitro receptor binding assays are performed to determine the affinity of Ramelteon metabolite M-II for melatonin receptors. Radioligand binding studies using membrane preparations from cells expressing the receptors are conducted. The compound's ability to displace a specific radiolabeled ligand from each receptor is measured to calculate its IC50 values.
|
| Cell Assay |
In vitro cell-based assays are conducted using cells expressing recombinant melatonin receptors. The cells are treated with Ramelteon metabolite M-II, and receptor activation is measured by assessing downstream signaling events such as inhibition of cAMP accumulation.
|
| Animal Protocol |
In vivo studies involving Ramelteon metabolite M-II-d3 are primarily focused on its role as an analytical standard for pharmacokinetic studies. The deuterated form is used as an internal standard for the quantification of ramelteon and its metabolites in biological samples using mass spectrometry.
|
| ADME/Pharmacokinetics |
Ramelteon metabolite M-II-d3 is used as an internal standard in pharmacokinetic studies to quantify ramelteon and its metabolites in biological samples using mass spectrometry. The compound's deuterium labeling allows for accurate quantification of the metabolite in complex biological matrices.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for Ramelteon metabolite M-II-d3. As a deuterated metabolite of an approved drug, its safety profile is expected to be similar to that of ramelteon.
|
| References | |
| Additional Infomation |
Ramelteon metabolite M-II-d3 is the deuterium-labeled form of the major metabolite of ramelteon, a melatonin receptor agonist used for the treatment of insomnia. It is used as an internal standard in analytical methods for the quantification of ramelteon and its metabolites. The compound is not intended for human therapeutic use and is strictly for research purposes.
|
| Molecular Formula |
C16H18D3NO3
|
|---|---|
| Molecular Weight |
278.36
|
| Exact Mass |
278.17
|
| CAS # |
1246812-22-5
|
| Related CAS # |
Ramelteon metabolite M-II;896736-21-3
|
| PubChem CID |
71751961
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
495.2±45.0 °C at 760 mmHg
|
| Flash Point |
253.3±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
2.06
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C([2H])([2H])C(C(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3)O
|
| InChi Key |
FGFNIJYHXMJYJN-PJCDIQNWSA-N
|
| InChi Code |
InChI=1S/C16H21NO3/c1-10(18)16(19)17-8-6-12-3-2-11-4-5-14-13(15(11)12)7-9-20-14/h4-5,10,12,18H,2-3,6-9H2,1H3,(H,17,19)/t10?,12-/m0/s1/i1D3
|
| Chemical Name |
3,3,3-trideuterio-2-hydroxy-N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5925 mL | 17.9624 mL | 35.9247 mL | |
| 5 mM | 0.7185 mL | 3.5925 mL | 7.1849 mL | |
| 10 mM | 0.3592 mL | 1.7962 mL | 3.5925 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
